NEW 2024 edition: Care Around Stillbirth and Neonatal Death Clinical Practice Guideline available now
Our Vision
Our Vision
Our vision is to reduce the devastating impact of stillbirth for women, families and the wider community through improving care to reduce the number of stillborn babies and to reduce the impact of this loss.
People + Partners
People + Partners
Meet the network of people, organisations, and professional institutions driving research and program implementation across the Stillbirth CRE.
Our work
Our Work
Explore some of the latest Stillbirth CRE research projects, scientific studies, and educational campaigns on stillbirth prevention and care after stillbirth.
Parent STories
News + Events
News + events
View the latest news and events from the Stillbirth CRE and our collaborating partners.
Get Involved
Get Involved
There's so many ways to contribute to stillbirth research. Sign up to our newsletter to stay in touch with the latest news, join our community, make a donation, or participate in research. Find out all the ways to Get Involved.
Safer Baby in pregnancy
Care after loss
Seeking Support
Research and news

Our aim is to improve care to reduce the number of stillborn babies and to reduce the impact of this loss.
Frequently asked questions
Get Involved

SLIPP: A Multi-centre randomised trial assessing time spent in supine position during sleep in the third trimester of pregnancy with or without a position aid

Project Status In Progress
Organisation Lead University of Sydney
Lead Investigator Adrienne Gordon
Program Area New Approaches To Prevention
Topic Testing Novel Interventions To Reduce Stillbirth Rates
Contact Adrienne Gordon at

This trial will test whether advice alone compared to advice and a pillow device best supports non-supine sleep using the Night Shift device as an objective measure of both sleep duration and position. This design could also be employed in the future for a roll out of sleep position interventions, but crucially the optimum intervention would need to be properly validated, which is what this trial aims to do.